Evidence Construction of Chuankezhi Injection Against Chronic Obstructive Pulmonary Disease: A Systematic Review and Network Pharmacology
Xuan Wei,Yu Zhong,Xiaofei Yi,Tingting Li,Zhougui Ling,Moyu Ming,Shuang Zhang,Zhiyi He
DOI: https://doi.org/10.2147/copd.s442281
2024-05-28
International Journal of COPD
Abstract:Xuan Wei, 1, 2, &ast Yu Zhong, 3, &ast Xiaofei Yi, 1 Tingting Li, 1 Zhougui Ling, 2 Moyu Ming, 2 Shuang Zhang, 1 Zhiyi He 1 1 Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning, People's Republic of China; 2 Department of Respiratory and Critical Care Medicine, The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, People's Republic of China; 3 Department of Emergency Medicine, The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, People's Republic of China &astThese authors contributed equally to this work Correspondence: Zhiyi He, Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Guangxi Medical University, NO. 6 Shuangyong Road, Qingxiu District, Nanning City, Guangxi Zhuang Autonomous Region, People's Republic of China, 530000, Tel +86 187 7801 7698, Email Objective: Chronic obstructive pulmonary disease (COPD) is a chronic respiratory disease with high prevalence, morbidity, and mortality. Chuankezhi (CKZ) injection, a Chinese patent medicine, has been commonly used for treating COPD. This study evaluated the clinical efficacy of CKZ injections in COPD patients and explored potential underlying mechanisms by integrating meta-analysis and network pharmacology. Research Methods: Randomized controlled trials (RCTs) were search in database by Web of Science, Cochrane Library and PubMed as of November 2022 for literature collection, and the Review Manager 5.4 was used to analyze the data. Through the network pharmacology method, the chemical components and their targets, as well as the disease targets were further analyzed. Results: A total of 15 RCTs including 1212 patients were included. The results of meta-analysis showed that CKZ injection can significantly improve the clinical effective rate (RR = 1.25, 95% CI: 1.14 to 1.36), and the clinical advantage was that it can significantly reduced acute exacerbation rate (RR = 0.29, 95% CI: 0.12 to 0.70) and COPD assessment test (CAT) scores (MD =− 4.62, 95% CI:-8.966 to-0.28). A total of 31 chemical compounds and 178 potential targets for CKZ injection were obtained from the online databases. Molecular docking revealed that most key components and targets could form stable structure. Conclusion: This systematic review with meta-analysis and network pharmacology demonstrates that CKZ could effectively improve the clinical efficacy and safety in the treatment of COPD. Such efficacy may be related to an anti-inflammatory effect and immunoregulation of CKZ via multiple components, multiple targets and multiple pathways. Keywords: meta-analysis, network pharmacology, chronic obstructive pulmonary disease, Chuankezhi injection Graphical Chronic obstructive pulmonary disease (COPD) is a common obstructive pulmonary disease, which can be prevented and treated. 1 It is characterized by persistent respiratory symptoms and airway obstruction induced by abnormalities in the airways alveoli as a result of prolonged exposure to noxious substances, particularly tobacco smoke and pollutants. 2 More than 300 million individuals worldwide suffer from COPD, which is now a significant global burden and is responsible for over 3.2 million annual deaths. 3 This disease will become the third biggest cause of mortality worldwide by 2030, according to the World Health Organization (WHO). 4 Importantly, reduplicative acute exacerbations can lead to a loss of pulmonary function and quality of life, culminating in death. 5 Thus, it is necessary to manage and prevent the progression of COPD 6 since inhaled corticosteroids and bronchodilators, which are the front-line therapies, are oftentimes ineffective. 7 Due to its relative safety and distinct superiority, Traditional Chinese medicine (TCM) has begun to gain international recognition during the past few years. 8 TCM is widely used in China to treat COPD patients and is gradually being accepted by the public due to its clinical efficacy and low incidence of side effects. 9 The Chuankezhi injection (CKZ) is made up of two traditional Chinese herbal medicines, Epimedium sagittatum (Sieb. et Zucc.) Maxim. and Morinda officinalis F.C.How. 10 These medicines are originated from the Shen Nong Ben Cao Jing, in which Epimedium sagittatum (Sieb. et Zucc.) Maxim.is thought to "warm the kidneys" and "help yang to stop coughing". 11 It is said in "Ben Cao Jing Shu" that Morinda officinalis F.C.How. can subsidiz -Abstract Truncated-
respiratory system